Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00900133 · ClinicalTrials.gov registry record

Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

A clinical trial, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
60
Enrollment target

NCT00900133 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00900133 has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
60 participants
Enrollment target

Study Summary

RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer. PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER immunoenzyme technique

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2005-01
Est. Completion 2006-12

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT00900133

The ClinicalTrials.gov registry entry for NCT00900133 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT00900133 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00900133 about?

NCT00900133 is a clinical study titled "Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer". RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer. PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the ...

What is the current status of trial NCT00900133?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2005-01. Estimated completion is 2006-12.

What interventions are being tested in trial NCT00900133?

The interventions under investigation include: laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER).

Who is sponsoring clinical trial NCT00900133?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.